Pfizer’s Latest Acquisition Strengthens The Case For PFE Stock
Pfizer is merging with Seagen in a $43 billion acquisition.Seagen was a sought-after target and Pfizer is succeeding where Merck failed, but it paid a premium to do so.Pfizer is expecting the acquisition to add $10 billion in revenue by 2030; early indications suggest analysts are less convinced.If Pfizer is right, this would be the element that was missing from an otherwise attractively priced stock.5 stocks we like better than PfizerQ4 2022 hedge fund letters, conferences and more Find A Qualified Financial AdvisorFinding a qualified financial advisor doesn't have to be hard. SmartAsset's fr...